Browse Topics
Tools
Editor's choice

Stuff Swiss people like, part two

Amanda of Queso Suizo blog continues her top 20 things that Swiss people like. More cowbell, anyone?

Win a bottle of whiskey!

Fill out an Expat Voices interview by 1 December and you can win a free bottle of whiskey!

Zurich’s boutique coffeehouse

Kerrin of MyKugelhopf visits Péclard, Zurich's new/old pastry shop and tea salon.

Internaxx Stock Market
Index Last Var.(%)
BEL 20 2119.3 0.50
DAX 5252.45 1.50
IBEX 30 10726.8 0.59
CAC 40 3377.59 1.40
FTSE 100 4564.5 0.79
AEX 276.85 0.95
DJIA 9096.72 -0.13
Nasdaq 1975.51 0.39
FTSE MIB 20341.67 1.65
TSX Composite 10570.54 -1.74
ASX 4148.9 -0.60
Hang seng 20135.5 -2.37
Straits Times 0.00
ISEQ 20 442.48 0.27
You are here: Home Health & Fitness Healthcare New antibiotic drug delayed

03/03/2009New antibiotic drug delayed

A Swiss drugs firm files claims against Johnson & Johnson for delaying ceftobiprole, an antibiotic for dangerous skin infections.

TRENTON — Johnson & Johnson's experimental antibiotic for dangerous skin infections had two more setbacks — a delay from European regulators, followed by legal action from its Swiss partner in developing the drug.

New Brunswick, New Jersey-based Johnson & Johnson long publicised ceftobiprole as a promising treatment for complicated skin and soft tissue infections, including MRSA, a deadly drug-resistant staph germ.

But the Food and Drug Administration twice delayed approval, most recently saying it wants more audit work done at clinical-investigator sites and answers to questions related to the monitoring done at these sites, where the drug was tested on patients.

In late February, Johnson & Johnson's Jansen-Cilag International NV unit said that the Committee for Medicinal Products for Human Use, an advisory panel of the European Medicines Agency, delayed approval pending completion of what's called a "good clinical practice inspection".

That mainly involves reviewing records at the European hospitals and other sites where patient testing was conducted, said J&J spokesman Ernie Knewitz.

On Tuesday, Basel, Switzerland-based Basilea Pharmaceutica, claiming financial damages from the repeated delays, submitted a request for arbitration to the Netherlands Arbitration Institute. A company statement said the arbitration request also involves milestone payments.

"In this environment, for small biotechs, any delay is absolutely devastating," said analyst Steve Brozak of WBB Securities.

"What is absolutely essential for" Basilea is just one of many projects for Johnson & Johnson, he added.

The company said it could win approval of seven other new drugs in 2009 alone.

Basilea, which discovered ceftobiprole, granted Johnson & Johnson an exclusive worldwide license in 2005 for the drug, which would be sold under the brand name Zevtera in European Union countries.

0 reactions to this article

Discussion Forums

Living in Switzerland

Part time Help Needed in Switzerland, by marthaa

Living in Switzerland

Anyone interested in starting a social club in Zurich?, by AshleyH

Living in Switzerland

Does anyone know Lausanne?, by poshgaffer

Living in Switzerland

house order rules in switzerland, by bluesfinger

CH Community Noticeboard

USA Meets Europe: A Forum for Young Leaders, by Mavrik

participate in the forums

find the business you need
Inside Expatica
How to keep fit in Switzerland

How to keep fit in Switzerland

Switzerland offers year-round sporting opportunities, from skiing in winter to swimming, golf and camping in summer.

How to open a Swiss bank account

How to open a Swiss bank account

How to open and close a Swiss bank account, plus information on confidentiality and security deposits.

Driving in Switzerland

Driving in Switzerland

How to obtain a licence, import vehicles and follow road rules in Switzerland.

Finding the perfect family home in Zurich

Finding the perfect family home in Zurich

Tips and info to help with the house hunt.